Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFY: Isatuximab, Iberdomide, and Dexamethasone in High-Risk Smouldering Myeloma
NCT06762769Phase 2Recruiting
- Sponsor
- University College London
- Start
- Jun 2025
- Primary completion
- Nov 2032
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab and iberdomide in multiple myeloma (MM), sponsored by University College London. Primary endpoints: Treatment deliverability at 2 years and Best overall response rate. Started Jun 2025; status: recruiting.
02
Drugs
isatuximabiberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06762769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762769.